Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2015

Date: September 16, 2015
Pages: 195
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CAB3E8D460CEN
Leaflet:

Download PDF Leaflet

Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2015’, provides an overview of the Cutaneous T-Cell Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Cutaneous T-Cell Lymphoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cutaneous T-Cell Lymphoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Cutaneous T-Cell Lymphoma Overview
Therapeutics Development
Pipeline Products for Cutaneous T-Cell Lymphoma - Overview
Pipeline Products for Cutaneous T-Cell Lymphoma - Comparative Analysis
Cutaneous T-Cell Lymphoma - Therapeutics under Development by Companies
Cutaneous T-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes
Cutaneous T-Cell Lymphoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Cutaneous T-Cell Lymphoma - Products under Development by Companies
Cutaneous T-Cell Lymphoma - Products under Investigation by Universities/Institutes
Cutaneous T-Cell Lymphoma - Companies Involved in Therapeutics Development
4SC AG
Affimed Therapeutics AG
Chipscreen Biosciences Ltd
Cornerstone Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc.
Eisai Co., Ltd.
Galderma S.A.
Innate Pharma SA
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
MedImmune, LLC
Neumedicines Inc.
Novartis AG
OncoSec Medical Inc.
Onyx Pharmaceuticals, Inc.
Sanofi
Seattle Genetics, Inc.
Soligenix, Inc.
Taiwan Liposome Company, Ltd.
TetraLogic Pharmaceuticals
Cutaneous T-Cell Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-dmDT390-bisFv - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AFM-13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alemtuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMP-224 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Angeloxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bexarotene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brentuximab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carfilzomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CIGB-128 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CPI-613 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CS-055 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DNA IL-12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IPH-4102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mogamulizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NMIL-121 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
quisinostat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
resminostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sapacitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SGX-301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SHP-141 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trifarotene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vinorelbine tartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cutaneous T-Cell Lymphoma - Recent Pipeline Updates
Cutaneous T-Cell Lymphoma - Dormant Projects
Cutaneous T-Cell Lymphoma - Discontinued Products
Cutaneous T-Cell Lymphoma - Product Development Milestones
Featured News & Press Releases
Aug 04, 2015: Soligenix Receives Orphan Drug Designation from the European Commission for SGX301 as a Treatment for Cutaneous T-Cell Lymphoma
Jun 23, 2015: Soligenix Announces Collaboration with the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation in Advancing its Phase 3 Study of SGX301 for the Treatment of Cutaneous T-Cell Lymphoma
Apr 07, 2015: DSG Partners with Soligenix to Battle Cutaneous T-Cell Lymphoma
Jan 07, 2015: FDA Grants Soligenix Fast Track”Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma
Dec 18, 2014: TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma
Nov 03, 2014: IPH 4102 Preclinical Data Published In Cancer Research
Sep 17, 2014: Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma
Aug 27, 2014: Innate Pharma's IPH4102 Receives Orphan Drug Designation In European Union
Apr 08, 2014: Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS in Key Countries
Apr 07, 2014: OncoSec Medical To Relaunch Phase II Cutaneous T-Cell Lymphoma Study at Key Centers of Excellence
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Cutaneous T-Cell Lymphoma, H2 2015
Number of Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd.1)
Products under Investigation by Universities/Institutes, H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by 4SC AG, H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Galderma S.A., H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Innate Pharma SA, H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by MedImmune, LLC, H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Neumedicines Inc., H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Novartis AG, H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by OncoSec Medical Inc., H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Sanofi, H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Soligenix, Inc., H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2015
Cutaneous T-Cell Lymphoma - Pipeline by TetraLogic Pharmaceuticals, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Cutaneous T-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015
Cutaneous T-Cell Lymphoma - Dormant Projects, H2 2015
Cutaneous T-Cell Lymphoma - Dormant Projects (Contd.1), H2 2015
Cutaneous T-Cell Lymphoma - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Cutaneous T-Cell Lymphoma, H2 2015
Number of Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

4SC AG
Affimed Therapeutics AG
Chipscreen Biosciences Ltd
Cornerstone Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc.
Eisai Co., Ltd.
Galderma S.A.
Innate Pharma SA
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
MedImmune, LLC
Neumedicines Inc.
Novartis AG
OncoSec Medical Inc.
Onyx Pharmaceuticals, Inc.
Sanofi
Seattle Genetics, Inc.
Soligenix, Inc.
Taiwan Liposome Company, Ltd.
TetraLogic Pharmaceuticals
Skip to top


T-Cell Lymphomas - Pipeline Review, H2 2014 US$ 1,500.00 Oct, 2014 · 143 pages

Ask Your Question

Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: